FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

Drugs & Targets

FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer

FDA approved sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

January 17, 2025

Vol.51 No.02

Drugs & Targets

FDA approves acalabrutinib + bendamustine and rituximab for mantle cell lymphoma

FDA approved acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.

January 17, 2025

Vol.51 No.02

Drugs & Targets

FDA issues proposed rule to limit nicotine in cigarettes

FDA issued a proposed rule that, if finalized, would make cigarettes and certain other combusted tobacco products minimally or nonaddictive by limiting the level of nicotine in those products. If finalized, the United States would be the first country globally to take such a bold, life-saving action to prevent and reduce smoking-related disease and death.

January 17, 2025

Vol.51 No.02

Drugs & Targets

FDA revokes authorization of Red No. 3 in food and ingested drugs

FDA is revoking the authorization for the use of FD&C Red No. 3 as a matter of law, based on the Delaney Clause of the Federal Food, Drug, and Cosmetic Act. FDA is amending its color additive regulations to no longer allow for the use of FD&C Red No. 3 in food and ingested drugs in response to a 2022 color additive petition.

January 17, 2025

Vol.51 No.02

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

YOU MAY BE INTERESTED IN

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer

FDA approves acalabrutinib + bendamustine and rituximab for mantle cell lymphoma

FDA issues proposed rule to limit nicotine in cigarettes

FDA revokes authorization of Red No. 3 in food and ingested drugs

Renew today!

Subscriber content

Never miss an issue!

Login